JP2022512920A5 - - Google Patents
Info
- Publication number
- JP2022512920A5 JP2022512920A5 JP2021524049A JP2021524049A JP2022512920A5 JP 2022512920 A5 JP2022512920 A5 JP 2022512920A5 JP 2021524049 A JP2021524049 A JP 2021524049A JP 2021524049 A JP2021524049 A JP 2021524049A JP 2022512920 A5 JP2022512920 A5 JP 2022512920A5
- Authority
- JP
- Japan
- Prior art keywords
- bound
- drug
- subject
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862755247P | 2018-11-02 | 2018-11-02 | |
| US62/755,247 | 2018-11-02 | ||
| US201962788714P | 2019-01-04 | 2019-01-04 | |
| US62/788,714 | 2019-01-04 | ||
| US201962789403P | 2019-01-07 | 2019-01-07 | |
| US62/789,403 | 2019-01-07 | ||
| US201962810173P | 2019-02-25 | 2019-02-25 | |
| US62/810,173 | 2019-02-25 | ||
| US201962826465P | 2019-03-29 | 2019-03-29 | |
| US62/826,465 | 2019-03-29 | ||
| PCT/US2019/059363 WO2020092881A1 (en) | 2018-11-02 | 2019-11-01 | Activatable anti-cd166 antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512920A JP2022512920A (ja) | 2022-02-07 |
| JP2022512920A5 true JP2022512920A5 (enExample) | 2022-11-09 |
Family
ID=68655704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524049A Pending JP2022512920A (ja) | 2018-11-02 | 2019-11-01 | 活性化可能抗ｃｄ１６６抗体およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220023439A1 (enExample) |
| EP (1) | EP3873531A1 (enExample) |
| JP (1) | JP2022512920A (enExample) |
| KR (1) | KR20210098989A (enExample) |
| CN (1) | CN113260383A (enExample) |
| AU (1) | AU2019370471A1 (enExample) |
| BR (1) | BR112021008526A2 (enExample) |
| CA (1) | CA3118445A1 (enExample) |
| IL (1) | IL282856A (enExample) |
| MX (1) | MX2021005116A (enExample) |
| SG (1) | SG11202104194SA (enExample) |
| WO (1) | WO2020092881A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL292798A (en) | 2015-05-04 | 2022-07-01 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses |
| CN111133006A (zh) | 2017-07-14 | 2020-05-08 | 西托姆克斯治疗公司 | 抗cd166抗体及其用途 |
| US20250333539A1 (en) | 2022-03-23 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| EP4504782A2 (en) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| JP2025525880A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| JP2025525867A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| EP4565250A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| AR130078A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| EP4695281A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| CN120936384A (zh) | 2023-04-12 | 2025-11-11 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2025094146A1 (en) * | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| AU2006284651C1 (en) | 2005-08-31 | 2013-09-12 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| CA2761310C (en) | 2009-05-07 | 2017-02-28 | Charles S. Craik | Antibodies and methods of use thereof |
| US9856314B2 (en) | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| AU2014298514A1 (en) * | 2013-08-02 | 2016-03-10 | Sanofi | Use of anti-MUC1 maytansinoid immunoconjugate antibody for the treatment of solid tumors |
| CN108112254B (zh) * | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| IL292798A (en) * | 2015-05-04 | 2022-07-01 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses |
| MX383464B (es) * | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| WO2019046652A1 (en) * | 2017-08-30 | 2019-03-07 | Cytomx Therapeutics, Inc. | ANTI-CD166 ACTIVABLE ANTIBODIES, AND METHODS OF USE |
-
2019
- 2019-11-01 US US17/290,694 patent/US20220023439A1/en not_active Abandoned
- 2019-11-01 EP EP19809291.8A patent/EP3873531A1/en not_active Withdrawn
- 2019-11-01 CA CA3118445A patent/CA3118445A1/en active Pending
- 2019-11-01 KR KR1020217016494A patent/KR20210098989A/ko not_active Ceased
- 2019-11-01 CN CN201980087098.XA patent/CN113260383A/zh active Pending
- 2019-11-01 MX MX2021005116A patent/MX2021005116A/es unknown
- 2019-11-01 BR BR112021008526-2A patent/BR112021008526A2/pt not_active Application Discontinuation
- 2019-11-01 SG SG11202104194SA patent/SG11202104194SA/en unknown
- 2019-11-01 AU AU2019370471A patent/AU2019370471A1/en not_active Abandoned
- 2019-11-01 JP JP2021524049A patent/JP2022512920A/ja active Pending
- 2019-11-01 WO PCT/US2019/059363 patent/WO2020092881A1/en not_active Ceased
-
2021
- 2021-05-02 IL IL282856A patent/IL282856A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512920A5 (enExample) | ||
| Singh et al. | Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer | |
| JP2020532509A5 (enExample) | ||
| Dastjerdi et al. | Corneal penetration of topical and subconjunctival bevacizumab | |
| JP2022082806A (ja) | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 | |
| Penha et al. | Retinal and ocular toxicity in ocular application of drugs and chemicals–part II: retinal toxicity of current and new drugs | |
| JP2009541492A5 (enExample) | ||
| CN103608029A (zh) | 包含阿柏西普、亚叶酸、5-氟尿嘧啶(5-fu)和伊立替康(folfiri)的组合物 | |
| CN107635583A (zh) | 用于治疗癌症的方法、组合物和试剂盒 | |
| JP2020517658A5 (enExample) | ||
| Orlandi et al. | Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind” side effect in a case report | |
| US20220249621A1 (en) | TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS | |
| Antaki et al. | Bilateral diffuse uveal melanocytic proliferation: report of a novel optical coherence tomography finding and clinical response to plasmapheresis | |
| US20240101666A1 (en) | Lag-3 antagonist therapy for lung cancer | |
| CN112566699B (zh) | 使用肽的联合疗法 | |
| Jianjiang et al. | Progress of anti-vascular endothelial growth factor therapy for ocular neovascular disease: benefits and challenges | |
| IL300052A (en) | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist | |
| WO2022226623A1 (en) | Method for allowing immune cells infiltration in tumors | |
| Fang et al. | PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cancer | |
| US20180243366A1 (en) | Drug containing recombinant mistletoe lectins for treating malignant melanoma | |
| KR20170090406A (ko) | 펩타이드-단백질 콘주게이트를 이용한 종양의 치료 | |
| JP6712226B2 (ja) | エキセメスタン及びエベロリムスと組み合わせてインスリン様成長因子（ｉｇｆ）受容体アンタゴニストを用いる癌治療 | |
| US20210228676A1 (en) | Combination Therapy With LIV1-ADC and PD-1 Antagonist | |
| Wong et al. | A PD-L1-targeted Probody TM Therapeutic Provides Anti-Tumor Efficacy While Minimizing Induction of Systemic Autoimmunity in Preclinical Studies | |
| CN106232621A (zh) | 用于治疗癌症的168a‑t2的多肽片段及包含其的组合物 |